Relationship between genetic polymorphisms in MCP-1, CCR-2, and non-small-cell lung cancer in the Han nationality of Northern China

L. Yang, J. Wang, F.-G. Li, M. Han, X.-J. Chang and Z.-T. Wang

Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, China

Corresponding author: Z.-T. Wang
E-mail: wztdoctor@163.com

Received May 13, 2014
Accepted October 25, 2014
Published April 22, 2015
DOI http://dx.doi.org/10.4238/2015.April.22.2

ABSTRACT. Lung cancer is a common malignant tumor worldwide and is now the leading cause of cancer-related deaths. Monocyte chemoattractant protein 1 (MCP-1) and its receptor chemokine receptor 2 (CCR-2) are important chemokines. We examined the polymorphisms of 338 unrelated patients with non-small cell lung carcinoma (NSCLC) and 200 unrelated healthy controls of Han nationality in Northern China using polymerase chain reaction-restriction fragment length polymorphism. We found a significant increase in the frequency of the MCP-1 AA genotype [0.293 vs 0.195, odds ratio (OR) = 1.71, 95% confidence interval (CI) = 1.13-2.60] and a significant decrease in the frequency of the GG genotype (0.290 vs 0.41, OR = 0.64, 95%CI = 0.47-0.87) in NSCLC patients compared to controls. The frequencies of AA-ww (0.151 vs 0.090, P = 0.041, OR = 1.80, 95%CI = 1.33-2.43) and AA-wm (0.136 vs 0.080, P = 0.049, OR = 1.81, 95%CI = 1.01-3.27) were higher in lung cancer patients than in healthy controls; the frequency of GG-wm (0.121 vs 0.190, P = 0.030, OR = 0.60, 95%CI
was lower in lung cancer patients than in healthy controls. Based on these results, the polymorphism in MCP-1 may be correlated with the development of NSCLC in the Han nationality of Northern China. However, the polymorphism in CCR-2 is not involved in NSCLC.

Key words: Chemokine receptor 2; Monocyte chemoattractant protein 1; Non-small cell lung carcinoma; Polymorphism

INTRODUCTION

Lung cancer is a common malignant tumor worldwide and has become the leading cause of cancer-related deaths (Youlden et al., 2008). Over the past decade, the morbidity and mortality of lung cancer have markedly increased in China (Yang et al., 2004). There are 2 main types of lung cancer: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC); NSCLC accounts for approximately 85% of all cases of lung cancer and shows poor prognosis (Tsitsias et al., 2013). To improve the poor prognosis of patients with NSCLC, the biology of lung cancer, including the effects of chemokines, must be further understood.

Monocyte chemoattractant protein 1 (MCP-1) is an important chemokine and was the third chemokine to be purified to homogeneity after platelet 4 and interleukin-8 (Matsushima et al., 1989). MCP-1 contains 76-amino acid residues, and its gene is located at 17q11.2-q12 (Rollins et al., 1991a). As a chemokine, MCP-1 can be produced by many fibroblasts, keratinocytes, and several cancer cell lines (Arndt et al., 2004; Lee et al., 2004; Mestdagt et al., 2006; Distler et al., 2009). Not only can it stimulate chemotaxis of peripheral blood monocytes and memory T cells, but it also can induce calcium flux, respiratory burst activity, and adhesion molecule and proinflammatory cytokine expression in monocytes (Rollins et al., 1991b; Carr et al., 1994; Charo and Ransohoff, 2006). Thus, MCP-1 may play an important role in the biology of NSCLC. Previous studies showed that MCP-1 is related to macrophage infiltration (Arenberg et al., 2000) and bone metastases in NSCLC (Cai et al., 2009). Chemokine receptor 2 (CCR-2) is a major receptor of MCP-1 that is largely produced by cancer cells and is responsible for recruiting macrophages to tumors such as bladder, cervix, ovary, lung, and breast tumors (Kurihara et al., 1997; MacKay, 2001). The G to A polymorphism at position 190 in the CCR-2 gene replaces valine with isoleucine at amino acid 64 (CC-2 V64I) (Smith et al., 1997). This polymorphism has been shown to be relevant to the susceptibility of some diseases (Manome et al., 1995; Nakayama et al., 2004; Ivansson et al., 2007; Prasad et al., 2007; Lin et al., 2012). A recent study suggested that the polymorphism in the MCP-1 distal regulatory region (-2518A/G) may be associated with susceptibility to NSCLC (Yang et al., 2010). As the receptor of MCP-1, the CCR-2 V64I polymorphism may be also relevant to the susceptibility to NSCLC. However, studies of the CCR-2 V64I polymorphism in NSCLC are limited. In addition, there have been no studies of polymorphisms in both genes.

In this study, we examined these polymorphisms in 338 unrelated patients with NSCLC and 200 unrelated healthy controls of Han nationality in Northern China using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The aim of our study was to investigate the role of polymorphisms MCP-1 -2518A/G and CCR-2 V64I in the genetic susceptibility to NSCLC.
MATERIAL AND METHODS

Subjects

The study enrolled 338 unrelated patients with NSCLC of Han nationality from Northern China. All patients were admitted to our hospital between October 2012 and September 2013, and lung cancer was diagnosed histologically. The subjects ranged in age from 35 to 78 years; 167 subjects were male and 171 were female. A total of 152 patients were diagnosed with squamous carcinoma and the other 186 patients were diagnosed with adenocarcinoma. The 200 controls were unrelated healthy people of Han nationality from Northern China, including 106 males and 94 females. All underwent a chest X-ray check and showed no anomalies. This study was approved by our institutional review board. All subjects provided informed consent for this study.

MCP-1 and CCR-2 genotyping

Genomic DNA from patients and controls was extracted using standard techniques from peripheral blood leukocytes. The A to G polymorphism of MCP-1 at position -2518 was identified by PCR and RFLP. We used the EQ5.5-50 EasyDo™ PCR PreMix system (SBS Genentech Co., Ltd., Beijing, China), which contained 2 U Taq DNA polymerase, 5 μL 10X PCR buffer, 5 μL loading dye, and 5 μL stabilizer. To this solution, we added 2 μL DNA, 2 μL of each forward and reverse primer, and 30 μL pure water. The forward primer for MCP-1 was 5’-TTCTCTTCTACGGGATCTGGG-3’ and the reverse primer was 5’-GTCTCTCCTGGCTTAGTCAT-3’. The forward primer for CCR-2 was 5’-ATCAGAAATACCAACGAGAGCGG-3’ and the reverse primer was 5’-ACACCAGACGAGGTTTCAGG-3’. PCR was performed under the following cycling condition: 95°C for 3 min, followed by 94°C for 40 s, 59°C for 40 s, and 74°C for 40 s for 35 cycles, with a final extension step at 72°C for 4 min. Three microliters of PCR product was digested with 2 U PvuII at 37°C for 60 min in a final volume of 10 μL for MCP-1. Three microliters of PCR product was digested with 2 U BtsCI at 50°C for 60 min in a final volume of 10 μL for CCR-2. The resulting fragments were separated by electrophoresis on a 3% agarose gel and were visualized under ultraviolet light after staining with ethidium bromide.

Statistical analysis

Genotype frequencies were calculated by direct counting. The frequency differences of the genotypes between the different groups were estimated using the chi-square test with SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA). The level of significance was set at P < 0.05. If the frequency difference of genotype showed statistical significance, the odds ratio (OR) and 95% confidence interval (CI) were calculated.

RESULTS

MCP-1 genotyping

The PCR products were 466-bp fragments. The PvuII-digested DNA segment from G/G homozygous individuals yielded 2 fragments: 327 and 139 bp; DNA from G/A hetero-
zygous individuals yielded 3 fragments: 466, 327, and 139 bp; DNA from A/A homozygous individuals yielded only 1 fragment: 466 bp (Figure 1).

Figure 1. Three genotypes separated by electrophoresis. Lanes 2, 3, 4, and 6 = AG genotype; lanes 1 and 7 = GG genotype; lanes 5 and 8 = AA genotype; lane I = 100-bp DNA marker.

**CCR-2 genotyping**

The PCR products were 669-bp fragments. The *Pvu*II-digested DNA segment from wild-type homozygous (w/w) individuals yielded 3 fragments: 102, 203, and 364 bp; DNA from heterozygous (w/m) individuals yielded 4 fragments: 102, 160, 203, and 364 bp; DNA from mutation-type homozygous (m/m) individuals yielded 3 fragments: 102, 160, and 203 bp (Figure 2).

Figure 2. Three genotypes separated by electrophoresis. Lanes 2, 3, and 5 = w/w genotype; lane 4 = w/m genotype; lanes 1 and 6 = m/m genotype; lane I = 100-bp DNA marker.

**Genotypes of MCP-1 and CCR-2 in NSCLC patients**

The distributions of the AA, AG, and GG genotypes of *MCP-1* as well as the distributions of the ww, wm, and mm genotypes of *CCR-2* are shown in Table 1. There was a significant increase in the frequency of the AA genotype (0.293 vs 0.195, OR = 1.71, 95%CI = 1.13-2.60) and a significant decrease in the frequency of the GG genotype (0.290 vs 0.41, OR = 0.64, 95%CI = 0.47-0.87) in NSCLC patients compared to controls. The frequencies of the ww, wm, and mm genotypes of *CCR-2* showed no difference between NSCLC patients and controls (Table 1).
Polymorphisms in MCP-1 and CCR-2 in NSCLC patients

Among the NSCLC patients, 152 patients were diagnosed with squamous carcinoma and 186 with adenocarcinoma. The frequencies of AA, AG, GG in MCP-1 and ww, wm, mm in CCR-2 are shown in Table 2. The difference of the genotypes in patients with squamous carcinoma and adenocarcinoma was not statistically significant.

Table 2. Comparison of the distribution of genotypes in squamous carcinoma and adenocarcinoma.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Squamous carcinoma</th>
<th>Adenocarcinoma</th>
<th>χ²</th>
<th>P</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>0.293 (99/338)</td>
<td>0.195 (39/200)</td>
<td>6.315</td>
<td>0.012</td>
<td>1.71 (1.13-2.60)</td>
</tr>
<tr>
<td>AG</td>
<td>0.417 (141/338)</td>
<td>0.395 (79/200)</td>
<td>0.255</td>
<td>0.613</td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>0.290 (98/338)</td>
<td>0.410 (82/200)</td>
<td>8.135</td>
<td>0.004</td>
<td>0.64 (0.47-0.87)</td>
</tr>
<tr>
<td>mm</td>
<td>0.041 (14/338)</td>
<td>0.065 (13/200)</td>
<td>1.446</td>
<td>0.226</td>
<td></td>
</tr>
<tr>
<td>mw</td>
<td>0.414 (140/338)</td>
<td>0.430 (86/200)</td>
<td>0.129</td>
<td>0.720</td>
<td></td>
</tr>
<tr>
<td>ww</td>
<td>0.545 (184/338)</td>
<td>0.505 (101/200)</td>
<td>0.782</td>
<td>0.376</td>
<td></td>
</tr>
</tbody>
</table>

Comparison of different combinations of MCP-1 and CCR-2 genotypes in patients with NSCLC and controls

Table 3 shows the frequencies of different combinations of MCP-1 and CCR-2 genotypes in patients with NSCLC and healthy controls. We found that the frequencies of combinations were higher in lung cancer patients than in healthy controls: AA-ww (0.151 vs 0.090, P = 0.041, OR = 1.80, 95%CI = 1.33-2.43), AA-wm (0.136 vs 0.080, P = 0.049, OR = 1.81, 95%CI = 1.01-3.27). The frequency of GG-wm was lower in lung cancer patients than in healthy controls. The frequencies in lung cancer patients and healthy controls were 0.121 and 0.190, respectively (P = 0.030, OR = 0.60, 95%CI = 0.38-0.95).

Table 3. Different combinations of MCP-1 and CCR-2 genotypes in patients with NSCLC and controls.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>NSCLC</th>
<th>Control</th>
<th>χ²</th>
<th>P</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA-mm</td>
<td>0.006 (2/338)</td>
<td>0.025 (5/200)</td>
<td>3.563</td>
<td>0.108</td>
<td></td>
</tr>
<tr>
<td>AG-mm</td>
<td>0.024 (8/338)</td>
<td>0.010 (2/200)</td>
<td>1.287</td>
<td>0.336</td>
<td></td>
</tr>
<tr>
<td>GG-mm</td>
<td>0.012 (4/338)</td>
<td>0.030 (6/200)</td>
<td>2.273</td>
<td>0.185</td>
<td></td>
</tr>
<tr>
<td>AA-ww</td>
<td>0.151 (51/338)</td>
<td>0.090 (18/200)</td>
<td>4.166</td>
<td>0.041</td>
<td>1.80 (1.33-2.43)</td>
</tr>
<tr>
<td>AG-ww</td>
<td>0.236 (80/338)</td>
<td>0.225 (45/200)</td>
<td>0.096</td>
<td>0.833</td>
<td></td>
</tr>
<tr>
<td>GG-ww</td>
<td>0.157 (53/338)</td>
<td>0.190 (38/200)</td>
<td>0.985</td>
<td>0.342</td>
<td></td>
</tr>
<tr>
<td>AA-wm</td>
<td>0.136 (46/338)</td>
<td>0.080 (16/200)</td>
<td>3.878</td>
<td>0.049</td>
<td>1.81 (1.01-3.27)</td>
</tr>
<tr>
<td>AG-wm</td>
<td>0.157 (53/338)</td>
<td>0.160 (32/200)</td>
<td>0.10</td>
<td>0.922</td>
<td></td>
</tr>
<tr>
<td>GG-wm</td>
<td>0.121 (41/338)</td>
<td>0.190 (38/200)</td>
<td>4.733</td>
<td>0.030</td>
<td>0.60 (0.38-0.95)</td>
</tr>
</tbody>
</table>
Comparison of different combinations of MCP-1 and CCR-2 genotypes in patients with squamous carcinoma and adenocarcinoma

Table 4 shows the frequencies of different combinations of MCP-1 and CCR-2 genotypes in patients with squamous carcinoma and adenocarcinoma. We found that the frequencies showed no difference between patients with squamous carcinoma and those with adenocarcinoma.

<table>
<thead>
<tr>
<th></th>
<th>Squamous carcinoma</th>
<th>Adenocarcinoma</th>
<th>$\chi^2$</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA-mm</td>
<td>(0/152)</td>
<td>(2/186)</td>
<td>1.644</td>
<td>0.504</td>
</tr>
<tr>
<td>AG-mm</td>
<td>(5/152)</td>
<td>(3/186)</td>
<td>1.017</td>
<td>0.475</td>
</tr>
<tr>
<td>GG-mm</td>
<td>(1/152)</td>
<td>(3/186)</td>
<td>0.652</td>
<td>0.630</td>
</tr>
<tr>
<td>AA-ww</td>
<td>(6/152)</td>
<td>(25/186)</td>
<td>0.877</td>
<td>0.349</td>
</tr>
<tr>
<td>AG-ww</td>
<td>(34/152)</td>
<td>(46/186)</td>
<td>0.258</td>
<td>0.611</td>
</tr>
<tr>
<td>GG-ww</td>
<td>(21/152)</td>
<td>(32/186)</td>
<td>0.726</td>
<td>0.394</td>
</tr>
<tr>
<td>AA-wm</td>
<td>(8/152)</td>
<td>(28/186)</td>
<td>0.734</td>
<td>0.392</td>
</tr>
<tr>
<td>AG-wm</td>
<td>(27/152)</td>
<td>(26/186)</td>
<td>0.906</td>
<td>0.361</td>
</tr>
<tr>
<td>GG-wm</td>
<td>(20/152)</td>
<td>(21/186)</td>
<td>0.274</td>
<td>0.601</td>
</tr>
</tbody>
</table>

DISCUSSION

As a potent chemokine, the influence of MCP-1 on monocytes and macrophages indicates its important role in tumor immunity. MCP-1 has been shown to suppress tumor growth both in T lymphocyte-independent and lymphocyte-dependent manners, where the effect is notably dose-dependent. The polymorphism in the MCP-1 distal regulatory region (-2518A/G) may affect the transcriptional activity and level of MCP-1 expression. Thus, the MCP-1 polymorphism may affect tumor immunity and result in inconsistencies in tumor susceptibility by influencing MCP-1 production. Our previous study showed that the frequency of the MCP-1 AA genotype was higher in NSCLC patients than in controls (P = 0.003, OR = 3.318, 95%CI = 1.480-6.652), and the frequency of the GG genotype was lower in NSCLC patients than in controls (P = 0.032, OR = 0.516, 95%CI = 0.282-0.944). The results of the present study showed that the frequency of the AA genotype was higher in NSCLC patients than in controls (0.293 vs 0.195, OR = 1.71, 95%CI = 1.13-2.60), and the frequency of the GG genotype was lower in NSCLC patients than in controls (0.290 vs 0.41, OR = 0.64, 95%CI = 0.47-0.87). This result was similar to our previous results suggesting that the polymorphism in MCP-1 influences the susceptibility to NSCLC.

CCR-2 is the receptor of MCP-1 and is expressed on monocytes, basophils, activated T-cells, dendritic cells, and natural killer cells. There are 2 transcribed isoforms of CCR-2, including CCR-2A and CCR-2B. The CCR-2 V64I polymorphism leads to enhanced gene expression of the CCR-2A isoform but no change in CCR-2B expression. The CCR-2A and CCR-2B isoforms have different functions; CCR-2B can provoke more inflammatory cells than CCR-2A (Wu et al., 2013). Thus, we hypothesized that the CCR-2 V64I polymorphism may be associated with the susceptibility to cancer. Previous studies have reported conflicting results regarding the CCR-2 polymorphism and the susceptibility to cervical cancer (Ivansson et al., 2007; Wu et al., 2013). However, there have been no reports examining the effect of the...
CCR-2 polymorphism and the susceptibility to NSCLC. Our results suggested that the CCR-2 polymorphism was not related to the susceptibility of NSCLC. Moreover, we examined different genotype combinations in MCP-1 and CCR-2 in NSCLC patients and controls. The results showed that the frequencies of AA-ww (0.151 vs 0.090, P = 0.041, OR = 1.80, 95%CI = 1.33-2.43) and AA-wm (0.136 vs 0.080, P = 0.049, OR = 1.81, 95%CI = 1.01-3.27) were higher in lung cancer patients than in healthy controls; the frequency of GG-wm (0.121 vs 0.190, P = 0.030, OR = 0.60, 95%CI = 0.38-0.95) was lower in lung cancer patients than in healthy controls. The significance of this observation is unclear because of the negative relationship between the polymorphism of CCR-2 and susceptibility to NSCLC.

Squamous carcinoma and adenocarcinoma are both categorized as NSCLC. We examined the genotypes of MCP-1 and CCR-2 in squamous carcinoma and adenocarcinoma patients and found no difference between the 2 groups.

CONCLUSIONS

The MCP-1 polymorphism may be correlated with the development of NSCLC in the Han nationality of Northern China. However, the polymorphism in the MCP-1 receptor, CCR-2, was not implicated in NSCLC. The effect of this genotype on NSCLC must be confirmed by a large-scale cross-sectional prospective study to clarify the mechanism of NSCLC development.

ACKNOWLEDGMENTS

We would like to acknowledge and thank our colleagues in the medical record department for their support and help.

REFERENCES


